EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Life Sciences - Clinical, TNT Asia
Director
Clinical trials have very detailed and precise processes and the logistical elements of these processes are critical Recent revisions to the pharmaceutical industrys regulatory laws as well as improved patent laws in countries such as Japan China and India have led to the burgeoning clinical trials market in Asia
Articles
Natural Polymers and Fibers in Drug Delivery
Advancements in drug delivery have become increasingly critical due to the growing demand for more effective targeted and personalized therapies Modern drug delivery systems are designed not only to enhance the bioavailability and release of drugs but also to optimise pharmacokinetic parameters such as absorption distribution metabolism and excretion ADME with the goal of improving therapeutic eff...
Research Insights
Biomarkers of mRNA Vaccine Efficacy Derived from Mechanistic Modeling of Tumor-immune Interactions
The success of mRNA vaccines against infectious diseases such as COVID has opened new avenues for their application in oncology In cancer immunotherapy mRNA vaccinestypically encapsulated in lipid nanoparticles LNPs
Case Studies
A Dose-Escalation Case Study Of A Second-Generationnon-Ansamycin HSP90 Inhibitor, Onalespib (AT13387), Incombination With Imatinib In Patients With Metastaticgastrointestinal Stromal Tumour
Abstract Gastrointestinal stromal tumours GIST are commonly driven by activating mutations in the KIT or PDGFRA receptor tyrosine kinases Although the initial response rates for newly diagnosed GIST to the tyrosine kinase inhibitorTKI imatinib can be most tumours ultimately become resistant commonly through secondary mutations or through alternative pa
Techno Trends
AusperBio Therapeutics Introduces Novel AHB-137 for Chronic Hepatitis B Treatment
AusperBio Therapeutics has introduced AHB a groundbreaking treatment for chronic hepatitis B CHB With approximately million people globally affected by chronic HBV and limited treatment options for a cure the disease
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Nanotechnology Strategies for Age –Related Macular Degeneration
Aira Sarkar is pursuing B. Tech (Pharmaceutical Chemistry and Technology) in Department of Pharmaceutical Science and Technology, Institute of Chemical Technology (ICT).
Sathish Dyawanapelly is working as an Assistant Professor in Department of Pharmaceutical Science and Technology, Institute of Chemical Technology (ICT).
Neoteric Solvents: A Paradigm Shift in Pharmaceutical Industrial Processes
Abhinab Goswamiis currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. He has published 01 research paper, 02 review articles and 01 book chapter in renowned journals/international book. His research focus lies in developing the neoteric solvents-based injectable dispersions for intra-auricular administration. He has also identified few neoteric solvents potential for converting them into nanomedicines.
Datta Maroti Pawde is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. He has published 05 research papers, 05 review articles and 03 book chapters in renowned journals/international book. Using the dual drug-loaded emulsions at lab-and pilot-scale, the intraarticular injections are developed to treat inflammatory conditions produced at articular or periarticular structures.
Syed Nazrin Ruhina Rahman is currently pursuing her Ph.D. from National Institute of Pharmaceutical Education and Research, Guwahati. She has published 02 research papers, 06 review articles and 04 book chapters in renowned journals/international book. Her research focus lies in managing the dry-eye syndrome by the topical application of cyclosporin A-loaded cationic emulsions.
Faculty Member, SB College of Pharmacy
Tamilvanan Shunmugaperumal is currently working at National Institute of Pharmaceutical Education and Research, Guwahati. He has published 58 research papers, 24 review articles and 08 book chapters in renowned journals international book. He is also author of 07 international books and holding 04 granted patents, 03 copyrights materials, etc.. His industrial-oriented research resulted in transfer of cationic emulsion formula from lab to industry.
USN Murty is currently working as Director of National Institute of Pharmaceutical Education and Research, Guwahati. He is the man of antimalarial research especially finding molecular leads from plant sources. He holds more than 100 research papers, few review articles and granted patents along with copyrights materials. His articulation in bioinformatics subjects is remarkable and he is the ardent user of artificial intelligence and machine learning in health-related platform.
Untapped Opportunities in Southeast Asia
Sue Lee has worked for World Courier for 25 years. During this time she has experienced a variety of customer service and operational functions, including the setting up of numerous, multi-national, clinical sites for the transportation of biological samples. She orchestrated the shipping of thousands of shipments with very specific temperature requirements to a host of challenging locations, and each presenting their own obstacles and dilemmas.
Are We Ready to Ship Billions of COVID Vaccines Worldwide?
President, Asia Pacific, Middle East and Africa, FedEx Express
The Transformative Impact of AI on Regulatory Affairs
Yu Han, DPhil in Engineering Science from the University of Oxford, brings a rich background with experience at manufacturer, global regulatory affairs CRO, and AI sector. Her expertise spans the regulatory landscapes of Asia, the US, and the EU, providing a comprehensive understanding of global pharmaceutical regulations. Passionate about combining AI technology with healthcare, Yu excels in creating innovative engineering tools to advance medical solutions. Her work leverages engineering methodologies to unravel complexities in the medical listing process, streamlining the global product flow.
<p> </p>
Email: yu.han@eng.ox.ac.uk
press releasesRead more...
Takeda and Zuellig Pharma Announce Strategic Regional Collaboration to Expand Patient Access to Takeda's Innovative Medicines Across Southeast Asia
Takeda and Zuellig Pharma today announced a strategic regional collaboration to enhance sustainable patient access to innovative medicines and healthcare solutions across Malaysia Indonesia and the Philippines Effective December the collaboration
Delonix Bioworks and A*STAR Infectious Diseases Labs Announce Research Collaboration to Advance Novel Engineered OMV Vaccine Candidates Against Klebsiella pneumoniae
Delonix Bioworks a clinicalstage biotechnology company pioneering nextgeneration outer membrane vesicle OMV vaccines today announced that it has entered into a Research Collaboration Agreement with ASTAR Infectious Diseases
Lonza and CMS Sign License Agreement for NeuroPortal™ TfR1 Blood-Brain Barrier Technology
Lonza and China Medical System Holdings Limited CMS announced today a global exclusive license agreement for the use of Lonzas NeuroPortal transferrin receptor TfR bloodbrain barrier BBB technology in up to two products targeting
Sino Biological Launches 4RISE™ High-Throughput Wet-Lab Services to Accelerate AI-Driven Drug Discovery
AIdriven protein design is accelerating the discovery of novel protein binders but experimental validation remains essential to determine whether computational designs translate into meaningful target interactions To bridge this gap Sino Biological Inc Shenzhen Stock Exchange SZ a global leader in r...
Innovent Announces Positive CHMP Opinion, Recommending Zybrivo® (sintilimab) for First-Line Treatment of Non-squamous Non-Small Cell Lung Cancer
Innovent Biologics Inc Innovent HKEX a worldclass biopharmaceutical company that develops manufactures and commercializes highquality medicines for the treatment of oncologic autoimmune cardiovascular and metabolic
EventsRead more...
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
01 - 03
Dec 2026Pharmaceutical Launch Excellence Summit
Novotel Amsterdam City, Nether...
01 - 03
Dec 202610th Antifibrotic Drug Development
Boston, MA at the Hotel Common...
02 - 04
Dec 2026Genome Informatics 2026
Wellcome Genome Campus, UK
03 - 04
Dec 2026Pharmacy and Pharmaceutical Conference
Madrid, Spain
03 - 04
Dec 2026Infectious and Rare Diseases
Paris, France
LATEST NEWSRead more...
OXB Partners with Aura Biosciences for Drug Manufacturing
OXB has confirmed a manufacturing and supply partnership with Aura Biosciences
GSK Receives Approval for Nelkarmi to Treat Advanced ALK-Positive Lung Cancer
GSK plc LSENYSE GSK has received accelerated approval from the US Food and Drug Administration FDA for Nelkarmi neladalkib a treatment for adults with locally advanced or metastatic anaplastic lymphoma kinase ALKpositive nonsmall cell lung cancer NSCLC
Erasca Enters into Collaboration with Bristol Myers Squibb to Evaluate Pancreatic Cancer Therapy
Erasca has entered into a clinical trial collaboration and supply agreement with Bristol Myers to evaluate the combination of ERAS and navlimetostat BMS an investigational PRMT inhibitor in patients with pancreatic cancer
OBI Pharma and Novartis Partner to Develop Next-Generation ADCs for Cancer Treatment
OBI Pharma has entered into a collaboration and licensing agreement with Novartis to develop nextgeneration antibodydrug conjugates ADCs using novel payloads and OBIs proprietary technology platforms
Merck to Acquire Rapid Micro Biosystems to Strengthen Automation in Pharmaceutical Quality Control
Merck has signed a definitive agreement to acquire Rapid Micro Biosystems a USbased provider of automated microbial qualitycontrol testing solutions for pharmaceutical manufacturing
Immuneering Enters into Collaboration with Astellas to Evaluate Combination Therapies for Pancreatic Cancer
Immuneering has entered into a clinical trial collaboration and supply agreement with Astellas Pharma to evaluate investigational combination therapies for patients with pancreatic cancer


